Vandetanib‐mediated photoinduced erythema multiforme: A case report and photobiological study.

Autor: Buján Bonino, Cecilia, Moreiras Arias, Noelia, López‐Pardo Rico, María, Sáez Padilla, José, González Vilas, Daniel, Suárez Peñaranda, José Manuel, Rodríguez Granados, María Teresa
Předmět:
Zdroj: Photodermatology, Photoimmunology & Photomedicine; May2023, Vol. 39 Issue 3, p276-278, 3p
Abstrakt: Vandetanib-mediated photoinduced erythema multiforme: A case report and photobiological study Keywords: erythema multiforme; photosensitivity disorder; vandetanib EN erythema multiforme photosensitivity disorder vandetanib 276 278 3 05/11/23 20230501 NES 230501 Vandetanib is a tyrosine kinase inhibitor, which acts over vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) receptors and rearranged during transfection (RET), among others; the latter explains its effectiveness against medullary thyroid cancer.[1] Adverse cutaneous reactions are common and take place in 28-71% of treated patients, including photosensitivity.[1] However, photoinduced erythema multiforme (PEM) secondary to this drug, a scarcely reported entity itself, has been reported only rarely.[[2]] A 59-year-old man presented in July 2021 with a pruriginous exanthem that had appeared 9 days earlier. Erythema multiforme, photosensitivity disorder, vandetanib. [Extracted from the article]
Databáze: Complementary Index
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje